Since the HER2 enriched TMA cases are from patients who were diagnosed with their primary breast cancer between March 1995 and November 2005 and adjuvant Trastuzumab was not approved by the FDA until 2006, patients primarily received chemotherapy without anti-HER2 therapy (Table 7). This evidence concerns the gene ERBB2 and breast carcinoma.